<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">surgonco</journal-id><journal-title-group><journal-title xml:lang="ru">Креативная хирургия и онкология</journal-title><trans-title-group xml:lang="en"><trans-title>Creative surgery and oncology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2076-3093</issn><issn pub-type="epub">2307-0501</issn><publisher><publisher-name>Башкирский государственный медицинский университет</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.24060/2076-3093-2021-11-1-85-91</article-id><article-id custom-type="elpub" pub-id-type="custom">surgonco-575</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОБЗОР ЛИТЕРАТУРЫ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>REVIEWS</subject></subj-group></article-categories><title-group><article-title>Перитонеальный канцероматоз: мировые научные школы и современное состояние вопроса</article-title><trans-title-group xml:lang="en"><trans-title>Peritoneal Carcinomatosis: Current State of the Art and Schools of Thought</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2047-963X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ганцев</surname><given-names>Ш. Х.</given-names></name><name name-style="western" xml:lang="en"><surname>Gantsev</surname><given-names>Sh. Kh.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ганцев Шамиль Ханафиевич — д.м.н., профессор, кафедра онкологии с курсами онкологии и патологической анатомии ИДПО </p><p>Республика Башкортостан, Уфа</p></bio><bio xml:lang="en"><p>Shamil Kh. Gantsev — Dr. Sci. (Med.), Prof., Department of Oncology with Courses of Oncology and Pathological Anatomy for Advanced Professional Education </p><p>Ufa</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9816-3614</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Забелин</surname><given-names>М. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Zabelin</surname><given-names>M. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Забелин Максим Васильевич — д.м.н., заместитель премьер-министра Правительства Республики Башкортостан, министр здравоохранения Республики Башкортостан </p><p>Республика Башкортостан, Уфа</p></bio><bio xml:lang="en"><p>Maksim V. Zabelin — Dr. Sci. (Med.), Deputy Prime Minister of the Government of the Republic of Bashkortostan, Minister of Health of the Republic of Bashkortostan </p><p>Ufa</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7562-5684</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ганцев</surname><given-names>К. Ш.</given-names></name><name name-style="western" xml:lang="en"><surname>Gantsev</surname><given-names>K. Sh.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ганцев Камиль Шамилевич — д.м.н., профессор, кафедра онкологии с курсами онкологии и патологической анатомии ИДПО</p><p>Республика Башкортостан, Уфа</p></bio><bio xml:lang="en"><p>Kamil Sh. Gantsev — Dr. Sci. (Med.), Prof., Department of Oncology with Courses of Oncology and Pathological Anatomy for Advanced Professional Education </p><p>Ufa</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8461-9243</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Измайлов</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Izmailov</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Измайлов Адель Альбертович — д.м.н., доцент, кафедра урологии с курсом ИДПО </p><p>Республика Башкортостан, Уфа</p></bio><bio xml:lang="en"><p>Adel A. Izmailov — Dr. Sci. (Med.), Assoc. Prof., Department of Urology with a course of Advanced Professional Education </p><p>Ufa</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9721-108X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кзыргалин</surname><given-names>Ш. Р.</given-names></name><name name-style="western" xml:lang="en"><surname>Kzyrgalin</surname><given-names>Sh. R.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кзыргалин Шамиль Римович — к.м.н., доцент, кафедра онкологии с курсами онкологии и патологической анатомии ИДПО </p><p>Республика Башкортостан, Уфа</p></bio><bio xml:lang="en"><p>Shamil R. Kzyrgalin — Cand. Sci. (Med.), Assoc. Prof., Department of Oncology with Courses of Oncology and Pathological Anatomy for Advanced Professional Education </p><p>Ufa</p></bio><email xlink:type="simple">ufa.shamil@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Башкирский государственный медицинский университет</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Bashkir State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Министерство здравоохранения Республики Башкортостан</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Ministry of Health of the Republic of Bashkortostan</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2021</year></pub-date><pub-date pub-type="epub"><day>20</day><month>04</month><year>2021</year></pub-date><volume>11</volume><issue>1</issue><fpage>85</fpage><lpage>91</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Ганцев Ш.Х., Забелин М.В., Ганцев К.Ш., Измайлов А.А., Кзыргалин Ш.Р., 2021</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="ru">Ганцев Ш.Х., Забелин М.В., Ганцев К.Ш., Измайлов А.А., Кзыргалин Ш.Р.</copyright-holder><copyright-holder xml:lang="en">Gantsev S.K., Zabelin M.V., Gantsev K.S., Izmailov A.A., Kzyrgalin S.R.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.surgonco.ru/jour/article/view/575">https://www.surgonco.ru/jour/article/view/575</self-uri><abstract><p>Перитонеальный канцероматоз (ПК) является глобальной проблемой современной онкологии, одним из наиболее неблагоприятных вариантов прогрессирования злокачественных опухолей различных локализаций. Несмотря на определенное внимание у онкологического сообщества к теме, в настоящее время лечение пациентов с явлениями ПК больше рассматривается в рамках только паллиативной помощи, что, в свою очередь, не дает достаточного импульса для изучения фундаментальных основ данного процесса. В настоящем обзоре литературы мы постарались комплексно охватить проблему ПК в глобальном ракурсе, в нем собрана ключевая информация о мировых научных школах, занимающихся данной темой. Кратко можно сказать, что на сегодняшний день перитонеальный канцероматоз с точки зрения общепринятой имплантационной теории рассматривается как локальный процесс. Вследствие этого все разработанные и разрабатываемые методы терапии носят локорегиональный характер: циторедуктивная хирургия, гипертермическая интраперитонеальная (внутрибрюшинная) химиотерапия. Недостаточная эффективность данных методов во многом связана с существенными пробелами в понимании логистики и сигналинга перитонеального канцероматоза. Ключевой международной организацией, консолидирующей специалистов в области перитонеального канцероматоза, является PSOGI. Несмотря на обширную географию членов PSOGI и глобальное обсуждение проблем лечения пациентов с перитонеальным канцероматозом, остается масса нерешенных научных вопросов, что, в свою очередь, создает сложности в разработке качественно новых эффективных методов терапии. На сегодняшний день можно выделить семь стран, где сформировались онкологические научные школы по изучению проблем ПК: США, Великобритания, Япония, Китай, Италия, Франция и Германия. Рассматривая перитонеальный канцероматоз как глобальную проблему, стоит отметить, что данной теме в России уделяется недостаточное внимание. Создание и развитие центров ПК в России послужит на благо онкологическим пациентам и развитию онкологии как науки в целом.</p></abstract><trans-abstract xml:lang="en"><p>Peritoneal carcinomatosis (PC) is a global challenge of modern oncology representing the most unfavourable scenario in diverse-locality tumourisation. Despite certain attention by the oncological community, the management of PC patients is currently palliative, which weakly promotes research into the basic principles of this morbidity. This literature review attempts to comprehensively cover the PC problematic from a global perspective and presents a key evidence on the world schools of thought in this area. Briefly taking, peritoneal carcinomatosis is viewed today as a local process in the conventional implantation theory, which imposes a locoregional character on all current or emerging therapies, such as cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Their inadequate efficacy is largely due to pronounced gaps in our understanding of PC logistics and signalling. PSOGI is a key organisation for centralising the specialty effort in peritoneal carcinomatosis. Despite its global geography and approach to PC discussion, a multitude of scientific questions remain unanswered impeding the establishment of novel effective therapies. The seven countries that nurtured distinguished schools of thought in PC studies are the USA, UK, Japan, China, Italy, France and Germany. Taking peritoneal carcinomatosis in a global perspective, an insufficient attention to its problematic in Russia should be addressed. The founding and fostering of national PC institutions will benefit cancer patients and progress in oncological science.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>перитонеальный канцероматоз</kwd><kwd>циторедуктивная хирургия</kwd><kwd>системная химиотерапия</kwd><kwd>гипертермическая внутрибрюшинная химиотерапия</kwd><kwd>научные школы</kwd></kwd-group><kwd-group xml:lang="en"><kwd>peritoneal carcinomatosis</kwd><kwd>cytoreductive surgery</kwd><kwd>systemic chemotherapy</kwd><kwd>hyperthermic intraperitoneal chemotherapy</kwd><kwd>school of thought</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Ганцев Ш.Х., Соломенный С.В., Ганцев К.Ш., Кзыргалин Ш.Р., Минигазимов Р.С., Логинова М.В. Оценка состояния серознолимфатических люков при перитонеальном канцероматозе по данным сканирующей электронной микроскопии (на примере диафрагмальной брюшины). Креативная хирургия и онкология. 2014;(4):4–10. DOI: 10.24060/2076-3093-2014-0-4-4-10</mixed-citation><mixed-citation xml:lang="en">Gantsev S.K., Solomenny S.V., Gantsev K.S., Kzyrgalin S.R., Minigazimov R.S., Loginova M.V. Assessment of serous lymph hatches in peritoneal carcinomatosis (diaphragmatic peritoneum) by scanning electron microscopy. Creative surgery and oncology. 2014;(4):4–10 (In Russ.). DOI: 10.24060/2076-3093-2014-0-4-4-10</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Sugarbaker P.H., Yonemura Y. Clinical pathway for the management of resectable gastric cancer with peritoneal seeding: best palliation with a ray of hope for cure. Oncology. 2000;58(2):96–107. DOI: 10.1159/000012086</mixed-citation><mixed-citation xml:lang="en">Sugarbaker P.H., Yonemura Y. Clinical pathway for the management of resectable gastric cancer with peritoneal seeding: best palliation with a ray of hope for cure. Oncology. 2000;58(2):96–107. DOI: 10.1159/000012086</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Cotte E., Passot G., Gilly F.N., Glehen O. Selection of patients and staging of peritoneal surface malignancies. World J Gastrointest Oncol. 2010;2(1):31–5. DOI: 10.4251/wjgo.v2.i1.31</mixed-citation><mixed-citation xml:lang="en">Cotte E., Passot G., Gilly F.N., Glehen O. Selection of patients and staging of peritoneal surface malignancies. World J Gastrointest Oncol. 2010;2(1):31–5. DOI: 10.4251/wjgo.v2.i1.31</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Sadeghi B., Arvieux C., Glehen O., Beaujard A.C., Rivoire M., Baulieux J., et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer. 2000;88(2):358–63. DOI: 10.1002/(sici)1097-0142(20000115)88:2&lt;358::aid-cncr16&gt;3.0.co;2-o</mixed-citation><mixed-citation xml:lang="en">Sadeghi B., Arvieux C., Glehen O., Beaujard A.C., Rivoire M., Baulieux J., et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer. 2000;88(2):358–63. DOI: 10.1002/(sici)1097-0142(20000115)88:2&lt;358::aid-cncr16&gt;3.0.co;2-o</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">European School of Peritoneal Surface Oncology (ESPSO). [cited 2020 Dec 20]. Available from: http://www.essoweb.org/school-of-peritonealsurface-oncology-es/</mixed-citation><mixed-citation xml:lang="en">European School of Peritoneal Surface Oncology (ESPSO) [cited 2020 Dec 20]. Available from:http://www.essoweb.org/school-of-peritonealsurface-oncology-es/</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Sugarbaker P.H., Chang D., Koslowe P. Prognostic features for peritoneal carcinomatosis in colorectal and appendiceal cancer patients when treated by cytoreductive surgery and intraperitoneal chemotherapy. Cancer Treat Res. 1996;81:89–104. DOI: 10.1007/978-1-4613-1245-1_9</mixed-citation><mixed-citation xml:lang="en">Sugarbaker P.H., Chang D., Koslowe P. Prognostic features for peritoneal carcinomatosis in colorectal and appendiceal cancer patients when treated by cytoreductive surgery and intraperitoneal chemotherapy. Cancer Treat Res. 1996;81:89–104. DOI: 10.1007/978-1-4613-1245-1_9</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Sugarbaker P.H., Stuart O.A. Unusually favorable outcome of 6 consecutive patients with diffuse malignant peritoneal mesothelioma treated with repeated doses of intraperitoneal paclitaxel. A case series. Surg Oncol. 2020;33:96–9. DOI: 10.1016/j.suronc.2020.01.009</mixed-citation><mixed-citation xml:lang="en">Sugarbaker P.H., Stuart O.A. Unusually favorable outcome of 6 consecutive patients with diffuse malignant peritoneal mesothelioma treated with repeated doses of intraperitoneal paclitaxel. A case series. Surg Oncol. 2020;33:96–9. DOI: 10.1016/j.suronc.2020.01.009</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Sugarbaker P.H. Intraperitoneal delivery of chemotherapeutic agents for the treatment ofperitoneal metastases: current challenges and how to overcome them. Expert Opin Drug Deliv. 2019;16(12):1393–401. DOI: 10.1080/17425247.2019.1693997</mixed-citation><mixed-citation xml:lang="en">Sugarbaker P.H. Intraperitoneal delivery of chemotherapeutic agents for the treatment ofperitoneal metastases: current challenges and how to overcome them. Expert Opin Drug Deliv. 2019;16(12):1393–401. DOI: 10.1080/17425247.2019.1693997</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Carr N.J., Bibeau F., Bradley R.F., Dartigues P., Feakins R.M., Geisinger K.R., et al. The histopathological classification, diagnosis and differential diagnosis of mucinous appendiceal neoplasms, appendiceal adenocarcinomas and pseudomyxoma peritonei. Histopathology. 2017;71(6):847–58. DOI: 10.1111/his.13324</mixed-citation><mixed-citation xml:lang="en">Carr N.J., Bibeau F., Bradley R.F., Dartigues P., Feakins R.M., Geisinger K.R., et al. The histopathological classification, diagnosis and differential diagnosis of mucinous appendiceal neoplasms, appendiceal adenocarcinomas and pseudomyxoma peritonei. Histopathology. 2017;71(6):847–58. DOI: 10.1111/his.13324</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Nors J., Funder J.A., Swain D.R., Verwaal V.J., Cecil T., Laurberg S., et al. Postoperative paralytic ileus after cytoreductive surgery combined with heated intraperitoneal chemotherapy. Pleura Peritoneum. 2019;5(1):20190026. DOI: 10.1515/pp-2019-0026</mixed-citation><mixed-citation xml:lang="en">Nors J., Funder J.A., Swain D.R., Verwaal V.J., Cecil T., Laurberg S., et al. Postoperative paralytic ileus after cytoreductive surgery combined with heated intraperitoneal chemotherapy. Pleura Peritoneum. 2019;5(1):20190026. DOI: 10.1515/pp-2019-0026</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Farquharson M., Hollingshead J., Brendan M. (eds). Farquharson’s Textbook of Operative General Surgery. 10th ed. CRC Press; 2014.</mixed-citation><mixed-citation xml:lang="en">Farquharson M., Hollingshead J., Brendan M. (eds). Farquharson’s Textbook of Operative General Surgery. 10th ed. CRC Press; 2014.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Brendan M., Heald R.J. (editors) Manual of Total Mesorectal Excision. CRC Press; 2013.</mixed-citation><mixed-citation xml:lang="en">Brendan M., Heald R.J. (editors) Manual of Total Mesorectal Excision. CRC Press; 2013.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Canbay E., Yonemura Y. Peritoneal Surface Malignancies: A Curative Approach. 10th ed. Springer; 2015.</mixed-citation><mixed-citation xml:lang="en">Canbay E., Yonemura Y. Peritoneal Surface Malignancies: A Curative Approach. 10th ed. Springer; 2015.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Ji Z.H., Peng K.W., Yu Y., Li X.B., Yonemura Y., Liu Y., et al. Current status and future prospects of clinical trials on CRS+HIPEC for gastric cancer peritoneal metastases. Int J Hyperthermia. 2017;33(5):562–70. DOI: 10.1080/02656736.2017.1283065</mixed-citation><mixed-citation xml:lang="en">Ji Z.H., Peng K.W., Yu Y., Li X.B., Yonemura Y., Liu Y., et al. Current status and future prospects of clinical trials on CRS+HIPEC for gastric cancer peritoneal metastases. Int J Hyperthermia. 2017;33(5):562–70. DOI: 10.1080/02656736.2017.1283065</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Coccolini F., Nardi M., Montori G., Ceresoli M., Celotti A., Cascinu S., et al. Neoadjuvant chemotherapyin advanced gastric and esophago-gastric cancer. Meta-analysis of randomized trials. Int J Surg. 2018;51:120–7. DOI: 10.1016/j.ijsu.2018.01.008</mixed-citation><mixed-citation xml:lang="en">Coccolini F., Nardi M., Montori G., Ceresoli M., Celotti A., Cascinu S., et al. Neoadjuvant chemotherapyin advanced gastric and esophago-gastric cancer. Meta-analysis of randomized trials. Int J Surg. 2018;51:120–7. DOI: 10.1016/j.ijsu.2018.01.008</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Lin Y.L., Zhang J., Yan F.C., Jiang X., Ma R., Yang Z.R., et al. Establishment of patient-derived xenograft model of peritoneal mucinous carcinomatosis with signet ring cells and in vivo study on the efficacy and toxicity of intraperitoneal injection of 5-fluorouracil. Cancer Med. 2020;9(3):1104–14. DOI:10.1002/cam4.2766</mixed-citation><mixed-citation xml:lang="en">Lin Y.L., Zhang J., Yan F.C., Jiang X., Ma R., Yang Z.R., et al. Establishment of patient-derived xenograft model of peritoneal mucinous carcinomatosis with signet ring cells and in vivo study on the efficacy and toxicity of intraperitoneal injection of 5-fluorouracil. Cancer Med. 2020;9(3):1104–14. DOI:10.1002/cam4.2766</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Yang X.J., Huang C.Q., Suo T., Mei L.J., Yang GL., Cheng F.L., et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol. 2011;18(6):1575–81. DOI: 10.1245/s10434-011-1631-5</mixed-citation><mixed-citation xml:lang="en">Yang X.J., Huang C.Q., Suo T., Mei L.J., Yang GL., Cheng F.L., et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol. 2011;18(6):1575–81. DOI: 10.1245/s10434-011-1631-5</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Huang C.Q., Min Y., Wang S.Y., Yang X.J., Liu Y., Xiong B., et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival for peritoneal carcinomatosis from colorectal cancer: a systematic review and meta-analysis of currentevidence. Oncotarget. 2017;8(33):55657–83. DOI: 10.18632/oncotarget.17497</mixed-citation><mixed-citation xml:lang="en">Huang C.Q., Min Y., Wang S.Y., Yang X.J., Liu Y., Xiong B., et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival for peritoneal carcinomatosis from colorectal cancer: a systematic review and meta-analysis of currentevidence. Oncotarget. 2017;8(33):55657–83. DOI: 10.18632/oncotarget.17497</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Guadagni S., Clementi M., Masedu F., Fiorentini G., Sarti D., Deraco M., et al. A pilot study of the predictive potential of chemosensitivity and gene expression assays using circulating tumour cells from patients with recurrent ovarian cancer. Int J Mol Sci. 2020;21(13):4813. DOI: 10.3390/ijms21134813</mixed-citation><mixed-citation xml:lang="en">Guadagni S., Clementi M., Masedu F., Fiorentini G., Sarti D., Deraco M., et al. A pilot study of the predictive potential of chemosensitivity and gene expression assays using circulating tumour cells from patients with recurrent ovarian cancer. Int J Mol Sci. 2020;21(13):4813. DOI: 10.3390/ijms21134813</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Belfiore A., Busico A., Bozzi F., Brich S., Dallera E., Conca E., et al. Molecular signatures for combined targeted treatments in diffuse malignant peritoneal mesothelioma. Int J Mol Sci. 2019;20(22):5817. DOI: 10.3390/ijms20225817</mixed-citation><mixed-citation xml:lang="en">Belfiore A., Busico A., Bozzi F., Brich S., Dallera E., Conca E., et al. Molecular signatures for combined targeted treatments in diffuse malignant peritoneal mesothelioma. Int J Mol Sci. 2019;20(22):5817. DOI: 10.3390/ijms20225817</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Glehen O., Gilly F.N. Quantitative prognostic indicators of peritoneal surface malignancy: carcinomatosis, sarcomatosis, and peritoneal mesothelioma. Surg Oncol Clin N Am. 2003;12(3):649–71. DOI: 10.1016/s1055-3207(03)00037-1</mixed-citation><mixed-citation xml:lang="en">Glehen O., Gilly F.N. Quantitative prognostic indicators of peritoneal surface malignancy: carcinomatosis, sarcomatosis, and peritoneal mesothelioma. Surg Oncol Clin N Am. 2003;12(3):649–71. DOI: 10.1016/s1055-3207(03)00037-1</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Alyami M., Hübner M., Grass F., Bakrin N., Villeneuve L., Laplace N., et al. Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications. Lancet Oncol. 2019;20(7):e368–77. DOI:10.1016/S1470-2045(19)30318-3</mixed-citation><mixed-citation xml:lang="en">Alyami M., Hübner M., Grass F., Bakrin N., Villeneuve L., Laplace N., et al. Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications. Lancet Oncol. 2019;20(7):e368–77. DOI:10.1016/S1470-2045(19)30318-3</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Glehen O., Osinsky D., Beaujard A.C., Gilly F.N. Natural history of peritoneal carcinomatosis from non gynecologic malignancies. Surg Oncol Clin N Am. 2003;12(3):729–39, XIII. DOI: 10.1016/s1055-3207(03)00044-9</mixed-citation><mixed-citation xml:lang="en">Glehen O., Osinsky D., Beaujard A.C., Gilly F.N. Natural history of peritoneal carcinomatosis from non gynecologic malignancies. Surg Oncol Clin N Am. 2003;12(3):729–39, XIII. DOI: 10.1016/s1055-3207(03)00044-9</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Glehen O., Gilly F.N., Cotte E. Hyperthermic intraperitoneal chemotherapy in advanced gastric cancer: the end of skepticism? Ann Surg Oncol. 2011;18(6):1524–6. DOI: 10.1245/s10434-011-1632-4</mixed-citation><mixed-citation xml:lang="en">Glehen O., Gilly F.N., Cotte E. Hyperthermic intraperitoneal chemotherapy in advanced gastric cancer: the end of skepticism? Ann Surg Oncol. 2011;18(6):1524–6. DOI: 10.1245/s10434-011-1632-4</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Rau B., Brandl A., Piso P., Pelz J., Busch P., Demtröder C., et al. Peritoneal metastasis in gastric cancer: results from the German database. Gastric Cancer. 2020;23(1):11–22. DOI: 10.1007/s10120-019-00978-0</mixed-citation><mixed-citation xml:lang="en">Rau B., Brandl A., Piso P., Pelz J., Busch P., Demtröder C., et al. Peritoneal metastasis in gastric cancer: results from the German database. Gastric Cancer. 2020;23(1):11–22. DOI: 10.1007/s10120-019-00978-0</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Vassos N., Piso P. Metastatic colorectal cancer to the peritoneum: current treatment options. Curr Treat Options Oncol. 2018;19(10):49. DOI: 10.1007/s11864-018-0563-8</mixed-citation><mixed-citation xml:lang="en">Vassos N., Piso P. Metastatic colorectal cancer to the peritoneum: current treatment options. Curr Treat Options Oncol. 2018;19(10):49. DOI: 10.1007/s11864-018-0563-8</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
